Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Inflammatory Bowel Disease

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

United European Gastroenterol J.

Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D

doi: 10.1177/2050640619840211.

Inflammatory Bowel Disease

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission

J Gastroenterol Hepatol.

Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A

doi: 10.1111/jgh.14751.

Inflammatory Bowel Disease

Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases

J Crohns Colitis.

Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F

doi: 10.1093/ecco-jcc/jjaa035.

COMMENTED

Inflammatory Bowel Disease

Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis

Int J Colorectal Dis.

Novello M, Stocchi L, Holubar S, Shawki S, Lipman J, Gorgun E, Hull T, Steele SR

doi: 10.1007/s00384-018-3212-6.

RECOMMENDED

Inflammatory Bowel Disease

Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series

★ 1 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

doi: 10.1093/ecco-jcc/jjaa078.

Inflammatory Bowel Disease

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study

Inflamm Bowel Dis.

Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV Jr

doi: 10.1093/ibd/izx076.

Inflammatory Bowel Disease

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Clin Gastroenterol Hepatol.

Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-Khac E, Meynier J, Fumery M

doi: 10.1016/j.cgh.2020.06.071.

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice

Biologicals.

Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T

doi: 10.1016/j.biologicals.

Related content

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission

Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases

Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis

Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice